Surgery Partners, Inc. has released its financial results for the third quarter of 2026, highlighting a slight decline in overall revenue but an increase in same-facility revenues. The company also announced an amendment to its merger agreement with HealthSpan Partners, raising the merger consideration to $25.00 per share. This strategic move underscores Surgery Partners' commitment to enhancing shareholder value amid a competitive landscape in the healthcare services industry.

On November 9, 2026, Surgery Partners, headquartered in Brentwood, Tennessee, filed a report detailing its performance for the three and nine months ending September 30, 2026. The company operates within the Services-General Medical & Surgical Hospitals, NEC sector and is traded on the Nasdaq under the ticker symbol SGRY. Recent filings include a 10-Q and multiple DEFA14A forms, all submitted on the same day as the 8-K.

The filing indicates that Surgery Partners experienced a revenue decrease of 0.8% for the third quarter, totaling $815.3 million compared to $821.5 million for the same period in 2025. However, same-facility revenues increased by 6.0%, showcasing a positive trend in core operations. The company reported a net loss of $21.1 million for the quarter, with an adjusted EBITDA of $132.7 million, down from $136.4 million in the previous year.

CEO Eric Evans commented on the results, stating, "Our financial results in the third quarter reflect the impact of the successful Idaho Falls divestiture and sustained momentum in our core business, underscoring the value of our short-stay surgical platform." He also noted that the amended merger agreement with HealthSpan Partners validates the company’s unique offerings and represents a compelling outcome for stakeholders.

Regarding the merger, the amendment comes after Surgery Partners received an unsolicited competing proposal. The new agreement increases the merger consideration to $25.00 per share, representing an enterprise value of up to approximately $6.0 billion. Additionally, the company will provide additional monthly cash payments to shareholders if the merger is not completed by March 1, 2027.

In light of the pending transaction, Surgery Partners will not host an earnings conference call and will no longer provide forward-looking guidance. The merger is expected to close in the first quarter of 2027, pending stockholder approval and regulatory approvals.

As of September 30, 2026, Surgery Partners reported cash and cash equivalents of $354.5 million, along with $692.8 million of borrowing capacity under its revolving credit facility. The company’s operating cash flows for the third quarter were $103.5 million, compared to $83.6 million for the same period in 2025.

With over 200 locations across 30 states, Surgery Partners continues to be a significant player in the healthcare services sector, focusing on high-quality, cost-effective surgical care. As the company navigates these changes, it aims to maintain its growth trajectory while enhancing value for its stakeholders.

Details were not available in the SEC filing regarding any upcoming votes or additional filings related to the merger.